Product image of Neloviren (Linagliptin) supplied by GNH India

Neloviren

Active Ingredient:
Linagliptin
Origin:
EU

Neloviren (Linagliptin)

Linagliptin, the active ingredient in Neloviren, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adults, helping to improve glycemic control when used with diet and exercise.
GNH India supplies Neloviren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmapath Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neloviren, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers HbA1c levels and improves overall glycemic control.
  • Type 2 diabetes mellitus (monotherapy): reduces fasting plasma glucose when diet and exercise are insufficient.
  • Type 2 diabetes mellitus (add‑on therapy): enhances post‑prandial glucose control when combined with other oral antidiabetics.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in increased circulating levels of the incretin hormones GLP‑1 and GIP. These hormones amplify glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby reducing hepatic glucose output and improving post‑prandial glucose excursions.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate headache.
  • Gastrointestinal upset: occasional nausea, abdominal discomfort or diarrhea.
  • Dizziness: occasional light‑headedness, especially on standing.
  • Upper respiratory infection: cough or sore throat.
  • Fatigue: mild tiredness reported by some patients.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with nausea, requiring immediate medical attention.
  • Severe hypersensitivity: rash, angioedema or anaphylactic reactions.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: rare autoimmune skin blistering disorder.

Precautions & Warnings

Linagliptin should be used with caution in specific clinical situations.

  • Renal impairment: assess renal function; dose adjustment may be required.
  • Hepatic disease: monitor liver enzymes regularly.
  • Cardiovascular disease: use with caution and monitor for any worsening symptoms.
  • Elderly patients: observe for hypoglycemia when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: safety not established; avoid unless clearly needed.
  • Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with several medicines that affect its plasma concentration or glucose‑lowering effect.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: heightened risk of hypoglycemia; monitor blood glucose.
  • Rifampicin: may lower therapeutic effect, requiring glycemic monitoring.
  • Diuretics: possible alteration of glucose control; observe patient response.

Frequently Asked Questions

Neloviren contains linagliptin, a DPP‑4 inhibitor that is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, usually as part of a comprehensive treatment plan that includes diet and exercise.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which raises levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping to lower blood glucose levels.

The appropriate dose of Neloviren is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Neloviren, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neloviren (linagliptin) shares the same class mechanism as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily excreted unchanged via the bile, which may reduce the need for dose adjustment in mild to moderate renal impairment compared with some alternatives.

Neloviren tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Neloviren is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious but rare risks include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Neloviren is contraindicated in patients with known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with severe hepatic disease, uncontrolled heart failure, or those taking medications that strongly interact with DPP‑4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT